Jnk signaling pathway-mediated regulation of Stat3 activation is linked to the development of doxorubicin resistance in cancer cell lines

Biochemical Pharmacology

Volumn 79, Issue 3, 2010, Pages 373-380

  Kim, Ju Hwa ^a   Lee, Seok Chul ^a   Ro, Jungsil ^a   Kang, Han Sung ^a   Kim, Hyung Sik ^b   Yoon, Sungpil ^a  

^a National Cancer Center   (South Korea)

^b Pusan National University   (South Korea)

Author keywords

cancer; DOX resistance; Doxorubicin; Jnk1; SP600125; Stat3

Indexed keywords

DOXORUBICIN; ETOPOSIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PACLITAXEL; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL NUCLEUS; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

CELL LINE, TUMOR; CELLS, CULTURED; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE SIGNALING SYSTEM; PROTEIN KINASE INHIBITORS; STAT3 TRANSCRIPTION FACTOR;

EID: 70450222114     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.09.008     Document Type: Article

References (36)

1. Humber C.E., Tierney J.F., Symonds R.P., Collingwood M., Kirwan J., Williams C., et al. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. Ann Oncol 18 (2007) 409-420
2. Llovet J.M. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 40 (2005) 225-235
3. Koceva-Chyla A., Jedrzejczak M., Skierski J., Kania K., and Jozwiak Z. Mechanisms of induction of apoptosis by anthraquinone anticancer drugs aclarubicin and mitoxantrone in comparison with doxorubicin: relation to drug cytotoxicity and caspase-3 activation. Apoptosis 10 (2005) 1497-1514
4. Suzuki F., Hashimoto K., Kikuchi H., Nishikawa H., Matsumoto H., Shimada J., et al. Induction of tumor-specific cytotoxicity and apoptosis by doxorubicin. Anticancer Res 25 (2005) 887-893
5. Esteva F.J., Valero V., Pusztai L., Boehnke-Michaud L., Buzdar A.U., and Hortobagyi G.N. Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist 6 (2001) 133-146
6. Ohtsuka T., Buchsbaum D., Oliver P., Makhija S., Kimberly R., and Zhou T. Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. Oncogene 22 (2003) 2034-2044
7. Sebolt-Leopold J.S. Development of anticancer drugs targeting the MAP kinase pathway. Oncogene 19 (2000) 6594-6599
8. Arslan M.A., Kutuk O., and Basaga H. Protein kinases as drug targets in cancer. Curr Cancer Drug Targets 6 (2006) 623-634
9. Brozovic A., and Osmak M. Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance. Cancer Lett 251 (2007) 1-16
10. Pommier Y., Sordet O., Antony S., Hayward R.L., and Kohn K.W. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 23 (2004) 2934-2949
11. Kohno M., and Pouyssegur J. Targeting the ERK signaling pathway in cancer therapy. Ann Med 38 (2006) 200-211
12. Bradham C., and McClay D.R. p38 MAPK in development and cancer. Cell Cycle 5 (2006) 824-828
13. Knuefermann C., Lu Y., Liu B., Jin W., Liang K., Wu L., et al. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 22 (2003) 3205-3212
14. Silva C.M. Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene 23 (2004) 8017-8023
15. Turkson J., and Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 19 (2000) 6613-6626
16. Zhou Y., Yau C., Gray J.W., Chew K., Dairkee S.H., Moore D.H., et al. Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer 7 (2007) 59
17. Hess J., Angel P., and Schorpp-Kistner M. AP-1 subunits: quarrel and harmony among siblings. J Cell Sci 117 (2004) 5965-5973
18. Basseres D.S., and Baldwin A.S. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 25 (2006) 6817-6830
19. Libermann T.A., and Zerbini L.F. Targeting transcription factors for cancer gene therapy. Curr Gene Ther 6 (2006) 17-33
20. Hwang M.N., Min C.H., Kim H.S., Lee H., Yoon K.A., Park S.Y., et al. The nuclear localization of SOCS6 requires the N-terminal region and negatively regulates Stat3 protein levels. Biochem Biophys Res Commun 360 (2007) 333-338
21. Jo C., Kim H., Jo I., Choi I., Jung S.C., Kim J., et al. Leukemia inhibitory factor blocks early differentiation of skeletal muscle cells by activating ERK. Biochim Biophys Acta 1743 (2005) 187-197
22. Lee K.H., Moon K.J., Kim H.S., Yoo B.C., Park S., Lee H., et al. Increased cytoplasmic levels of CIS, SOCS1, SOCS2, or SOCS3 are required for nuclear translocation. FEBS Lett 582 (2008) 2319-2324
23. Reid G.A., and Schatz G. Import of proteins into mitochondria. Extramitochondrial pools and post-translational import of mitochondrial protein precursors in vivo. J Biol Chem 257 (1982) 13062-13067
24. Alao J.P. The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer 6 (2007) 24
25. Magnani M., Crinelli R., Bianchi M., and Antonelli A. The ubiquitin-dependent proteolytic system and other potential targets for the modulation of nuclear factor-kB (NF-kB). Curr Drug Targets 1 (2000) 387-399
26. Razis E.D., and Fountzilas G. Paclitaxel: epirubicin in metastatic breast cancer-a review. Ann Oncol 12 (2001) 593-598
27. Bennett B.L., Sasaki D.T., Murray B.W., O'Leary E.C., Sakata S.T., Xu W., et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 98 (2001) 13681-13686
28. Nitiss J.L. DNA topoisomerases in cancer chemotherapy: using enzymes to generate selective DNA damage. Curr Opin Investig Drugs 3 (2002) 1512-1516
29. Proietti C., Salatino M., Rosemblit C., Carnevale R., Pecci A., Kornblihtt A.R., et al. Progestins induce transcriptional activation of signal transducer and activator of transcription 3 (Stat3) via a Jak- and Src-dependent mechanism in breast cancer cells. Mol Cell Biol 25 (2005) 4826-4840
30. Garcia R., Bowman T.L., Niu G., Yu H., Minton S., Muro-Cacho C.A., et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20 (2001) 2499-2513
31. Bogoyevitch M.A., Boehm I.I., Oakley A., Ketterman A.J., and Barr R.K. Targeting the JNK MAPK cascade for inhibition: basic science and therapeutic potential. Biochim Biophys Acta 1697 (2004) 89-101
32. Liu A.M., Lo R.K., Wong C.S., Morris C., Wise H., and Wong Y.H. Activation of STAT3 by G alpha(s) distinctively requires protein kinase A, JNK, and phosphatidylinositol 3-kinase. J Biol Chem 281 (2006) 35812-35825
33. Miyazaki T., Bub J.D., and Iwamoto Y. c-Jun NH(2)-terminal kinase mediates leptin-stimulated androgen-independent prostate cancer cell proliferation via signal transducer and activator of transcription 3 and Akt. Biochim Biophys Acta 1782 (2008) 593-604
34. Lau C.K., Yang Z.F., Lam S.P., Lam C.T., Ngai P., Tam K.H., et al. Inhibition of Stat3 activity by YC-1 enhances chemo-sensitivity in hepatocellular carcinoma. Cancer Biol Ther 6 (2007) 1900-1907
35. Gariboldi M.B., Ravizza R., Molteni R., Osella D., Gabano E., and Monti E. Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line. Cancer Lett 258 (2007) 181-188
36. Bewry N.N., Nair R.R., Emmons M.F., Boulware D., Pinilla-Ibarz J., and Hazlehurst L.A. Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Mol Cancer Ther 7 (2008) 3169-3175